SETTLE

This page contains information on SETTLE for veterinary use.
The information provided typically includes the following:
  • SETTLE Indications
  • Warnings and cautions for SETTLE
  • Direction and dosage information for SETTLE

SETTLE

This treatment applies to the following species:
Manufacturer: Bioniche Animal Health

MYCOBACTERIUM CELL WALL FRACTION IMMUNOSTIMULANT

For use by or under the direction of a licensed veterinarian

For intravenous / intrauterine use only

SETTLE Indications

Recommended as an aid in the treatment of equine endometritis caused by Streptococcus zooepidemicus.

Dosage & Administration: Administer 1.5 ml by intrauterine instillation with a sterile catheter or by intravenous injection into the jugular vein during the early estrus period. Treatment may be repeated at subsequent natural or induced estrus periods.

Intravenous: Administer 1.5ml of SETTLE by intravenous injection into the jugular vein during the early estrus. Use strict aseptic technique.

Intrauterine: Administer 1.5ml by intrauterine instillation using strict aseptic technique. Dilute 1.5ml of SETTLE in sterile lactated ringers, normal saline, water for injection or semen extender to provide an approximate final volume of 25-50ml. Aseptically administer the diluted solution into the uterus using a sterile catheter.

SETTLE Caution

Store at 2°-7°C. (35°-45°F). Do not freeze. Mix thoroughly before injecting. Use entire contents when first opened. Contains gentamicin as preservative. Do not administer within 21 days of slaughter. If anaphylaxis occurs, administer epinephrine or equivalent. KEEP OUT OF THE REACH OF CHILDREN.

Contra-indications: Cortisone reduces the production of interleukin-1 (IL-1). Mares being treated with corticosteroids or ACTH may not respond to SETTLE therapy.

Product Description: SETTLE is an emulsion of purified mycobacterium cell walls that have been extracted by a process that reduces their toxic and allergic effects. SETTLE enhances the innate humoral immune responses by activating macrophages and stimulating the cloning of polymorphonuclear leukocytes (PMN). These activated phagocytic cells stimulate a cytokine cascade that results in the destruction of bacteria, such as Streptococcus zooepidemicus.

Side Effects: Mild fever, drowsiness, and decreased appetite may occur for 1 to 2 days following intravenous injection. These are normal responses to the release of IL-1. An elevated body temperature enhances the immune function by stimulating leukocyte activity and thus is not an adverse side effect.

How supplied: SETTLE is available in cartons containing 6 x 1.5ml single dose vials.

Manufactured by: Bioniche Animal Health USA, Inc., Athens, GA 30601

U.S. Vet. Lic. No. 289

(706) 549-4503

NAC No.: 11070100

BIONICHE ANIMAL HEALTH USA, INC.
1551 JENNINGS MILL RD., SUITE 3200A, BOGART, GA, 30622
Telephone:   706-549-4503
Order Desk:   888-549-4503
Fax:   706-548-0659
Website:   www.bionicheanimalhealth.com
Email:   vet.usa@bioniche.com
Every effort has been made to ensure the accuracy of the SETTLE information published above. However, it remains the responsibility of the readers to familiarize themselves with the product information contained on the US product label or package insert.

Copyright © 2014 North American Compendiums. Updated: 2014-05-28

(web2)